Natural Beauty Bio-Technology Limited (00157.HK) reported a turnaround for the year ended 31 December 2025, swinging to a net profit of HK$10.58 million from a HK$103.62 million loss in 2024 on the back of stronger mainland China sales.

Revenue climbed 52.4 % to HK$538.83 million, led by a 504.7 % surge in beauty-apparatus sales to HK$175.77 million. Conventional skincare and related products contributed HK$355.33 million, up 10.6 %, while service income more than doubled to HK$7.73 million.

By geography, mainland China delivered HK$445.84 million, up 74.7 % and accounting for 82.7 % of group turnover. Taiwan slipped 2.6 % to HK$89.72 million; other markets contributed HK$3.28 million.

Gross profit improved 45.0 % to HK$293.34 million, although gross margin eased to 54.4 % from 57.2 % due to changes in product mix. Operating profit reached HK$23.18 million, versus a HK$97.16 million operating loss a year earlier. Basic earnings per share were HK$0.0053 (2024: loss of HK$0.0518).

The board did not recommend a dividend (2024: nil).

Total assets rose to HK$925.59 million, with net assets at HK$473.98 million. Cash and cash equivalents stood at HK$104.30 million, while interest-bearing borrowings increased to HK$294.86 million, lifting the gearing ratio to 62.2 % (2024: 43.0 %). Net operating cash outflow was HK$15.50 million.

Capital expenditure reached HK$46.50 million, mainly for a new mainland manufacturing plant and retail expansion.

No share options or share awards were granted during the year.